Clinical Trials Logo

Filter by:
NCT ID: NCT06067009 Recruiting - Kidney Diseases Clinical Trials

Feasibility Trial of a Stakeholder-enhanced Lay-navigator-delivered Intervention (ImPart-Multi)

ImPart-Multi
Start date: March 20, 2024
Phase: N/A
Study type: Interventional

We seek to explore the feasibility and acceptability of participation in a decision-support training program led by lay navigators. ImPart-Multi, an education-telehealth-based, is designed to empower Black chronic kidney disease patients (CKD) patients and their care partner to seek the resources and support needed to be activated allies when making health-related decisions. Participants, based on random assignment, will participate in survey completion at study start and at 12 and 24 weeks of enrollment, and will complete 1, 3, or 4 education sessions via telehealth or audio connection. Participants will also complete an interview to share their thoughts on the program and other factors of interest.

NCT ID: NCT06066996 Recruiting - E-cigarette Use Clinical Trials

Evaluation of the Electronic Cigarette Withdrawal Syndrome

Start date: November 28, 2023
Phase: Early Phase 1
Study type: Interventional

The goal of this project is to rigorously evaluate the nature of e-cigarette withdrawal in exclusive e-cigarette users during a monitored abstinence period and the role of nicotine in the expression of this withdrawal syndrome.

NCT ID: NCT06066983 Recruiting - Clinical trials for Autism Spectrum Disorder

DINO RCT - Treating Anxiety in Children With Autism

Start date: January 2, 2024
Phase: N/A
Study type: Interventional

Anxiety is prevalent in young children, under 7 years of age, with autism. Yet, few studies have examined anxiety interventions for this age range, and only one anxiety treatment study has included young children with cognitive and language delays. Anxiety treatment models utilizing cognitive-behavioral therapy (CBT), adapted for children with autism, are empirically supported in school-age autistic children. Further, preliminary evidence suggests CBT approaches may reduce intolerance of uncertainty (IU), a mechanistic construct that may contribute to the maintenance of anxiety in autistic children. This study seeks to address the existing gap in anxiety treatment by examining the feasibility and preliminary efficacy of a novel, telehealth CBT intervention, DINO Strategies for Anxiety and intolerance of Uncertainty Reduction (DINOSAUR), which targets both anxiety and IU in young autistic children.

NCT ID: NCT06066957 Recruiting - Clinical trials for Cytomegalovirus Infections

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

Start date: April 4, 2024
Phase: Phase 2
Study type: Interventional

Open label study to determine tolerability and efficacy of letermovir for CMV prophylaxis in heart and lung transplant recipients and compare it to the efficacy of valganciclovir historical controls. The study hypotheses are: 1. Letermovir prophylaxis will be associated with similar rates of CMV infection as valganciclovir among heart and lung transplant recipients 2. Letermovir will be better tolerated than valganciclovir for CMV prophylaxis in heart and lung transplant recipients, with a higher proportion of days of completed therapy with correct dosing during the planned prophylaxis period 3. Letermovir will have a lower rate of neutropenia than valganciclovir when used for CMV prophylaxis in heart and lung transplant recipients 4. Incorrect renal dosing will occur less frequently with letermovir than with valganciclovir when used for CMV prophylaxis in heart and lung transplant recipients

NCT ID: NCT06066879 Recruiting - Fusion of Spine Clinical Trials

Pre-Operative Ketamine Infusion for Post Operative Pain Control After Revision Spinal Surgery

KIPSs
Start date: September 18, 2023
Phase: Phase 4
Study type: Interventional

To determine if a pre-operative ketamine infusion would provide a similar decrease in post-operative analgesic and opioid consumption as intra-operative ketamine, but expand the monitoring period through the post-operative phase up to 90 days. Hypothesis is that pre-operative ketamine infusion will lead to a decrease in narcotic consumption from baseline following an elective cervical or lumbar fusion, leading to increased functionality and quality of life for these patients.

NCT ID: NCT06066853 Not yet recruiting - Fibromyalgia Clinical Trials

MDMA-assisted Therapy for Fibromyalgia

Start date: August 2024
Phase: Early Phase 1
Study type: Interventional

Fibromyalgia is a debilitating chronic pain disorder. Based on prior research with MDMA, it can be hypothesized MDMA-assisted therapy in fibromyalgia patients may increase the range of positive emotions, interpersonal trust, and heighten the state of empathic rapport that can lead to an enhanced patient-clinician interaction and to initiate reattribution processes targeting dysfunctional thoughts towards pain. Therapeutic alliance, i.e. a positive patient-clinician relationship, is already acknowledged as an essential component for MDMA-assisted therapy. Despite its importance, the patient-clinician interaction and the neuroscience supporting patient/clinician therapeutic alliance has received almost no attention in MDMA research. The investigators will examine the potential therapeutic benefit of MDMA-assisted therapy for fibromyalgia. Additionally, this study will also target secondary objectives including the investigation of the clinical and physiological response (i.e. brain-to-brain concordance) supporting enhanced patient-clinician therapeutic alliance in fibromyalgia patients. The study includes two Experimental Sessions of therapy with MDMA combined with neuroimaging, along integrative therapy, baseline neuroimaging, and a 3 month follow up.

NCT ID: NCT06066788 Recruiting - Stroke Clinical Trials

Cognitive Strategies for Improving Health Outcomes And Managing Risk Post-Stroke

CHAMPS
Start date: February 15, 2024
Phase: N/A
Study type: Interventional

The proposed research will further develop the CHAMPS intervention which is self-management intervention to learn new skills, despite current health status of experience a stroke. The study seeks to determine feasibility and compare pre- to post-intervention change including cardiovascular risk, quality of life, self-efficacy, recurrent stroke, hospital readmission, and perceived decline in health and function.

NCT ID: NCT06066749 Enrolling by invitation - Healthy Clinical Trials

Efficacy of Respiratory Protection Against the Effects of Wood Smoke Exposure in Young Healthy Adults (MASKON)

MASKON
Start date: June 2024
Phase: N/A
Study type: Interventional

Purpose: The study is designed to investigate cardiovascular effects of young healthy human subjects exposed to wood smoke. Participants: Approximately 30 young (18-35 years old) healthy subjects to complete. Procedure (methods): After consenting to participate in the study, participants will undergo exposure to approximately 500 μg/m^3 wood smoke for 2 hours while exercising intermittently (15 min exercise followed by 15 min rest) on a stationary bike at a workload sufficient to maintain approximately 12 L/min/m^2 minute ventilation. There are a total of three separate exposure sessions. During the first two exposure sessions, participants will wear, in randomized order, a half-face elastomeric respirator fitted with particulate filters alone (hereafter referred to as "PM mask") or particulate filters and a hydrocarbon sorbent (hereafter referred to as "VOC mask"). During the third exposure session, participants will be randomly assigned to wear either a surgical mask or an N95 respirator. Venous blood samples and measurements of lung, cardiac and vascular function will be made prior to and immediately following each exposure. Induced sputum samples and nasal epithelial lining fluid will be collected approximately 24 hours post each exposure.

NCT ID: NCT06066723 Not yet recruiting - Clinical trials for Cystic Fibrosis in Children

19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease

Start date: June 2024
Phase:
Study type: Observational

This study capitalizes on the emerging technology of 19F MRI, using conventional 'thermally' polarized perfluorinated gas (perfluoropropane, or PFP) mixed with oxygen and studied with magnetic resonance imaging (MRI) to visualize ventilation. This technique has not been studied in children. Children and adolescents (6-17 years old) with cystic fibrosis (CF) who have normal spirometry will undergo 19F MRI with the inhalation of an inert contrast gas to study ventilation. Comparisons will be made to a cohort of healthy children (6-17 years old) who will perform the same measures. The primary outcome measure is the feasibility of conducting these studies in the pediatric population. Parallel performance of multiple breath nitrogen washout (MBW) and spirometry will be used to compare the sensitivity of these outcomes to the presence of mild lung disease in these children. Finally, the investigators will compare data obtained during standard breath holds with a novel "free-breathing" technique that will eliminate the need for breath holds during MRI acquisition.

NCT ID: NCT06066710 Recruiting - Clinical trials for Aphasia, Primary Progressive

Propranolol in Primary Progressive Aphasia

Start date: October 2024
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure. This research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.